CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities
Net loss	$ (5,254,652)	$ (9,495,347)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	12,753	12,753
(Gain) loss on debt extinguishment	(2,434,661)	2,268,373
Decrease in fair value of derivative liabilities	(948)	(47,331)
Amortization of discount on notes payable	2,064,774	2,191,248
Accrued interest on patents purchased	123,233	0
Amortization of patents and acquired contracts	1,217,985	1,237,115
Net cost of patents sold	0	215,372
Stock-based compensation	545,626	843,386
Changes in operating assets and liabilities
Accounts receivable	8,880	219,851
Inventories	0	130,155
Prepaid expenses and other current assets, net	(646,943)	(21,441)
Deferred expenses	(27,391)	300,833
Deposits and other assets	0	(10,000)
Accounts payable	777,559	114,512
Accrued expenses and other current liabilities	407,267	483,961
Deferred revenue	450,000	746,429
Net cash used in operating activities	(2,756,518)	(810,131)
Cash flows from financing activities
Proceeds from issuance of preferred stock, net of issuance costs	5,221,998	0
Proceeds from issuance of common stock, net of issuance costs	1,182,278	1,835,000
Proceeds from issuance of notes payable	0	1,126,900
Payments on Fortress notes payable	(1,640,016)	(2,147,000)
Redemption of preferred stock	(2,500,000)	0
Payments on related party note payable	(50,000)	(80,000)
Net cash provided by financing activities	2,214,260	734,900
Net decrease in cash and cash equivalents	(542,258)	(75,231)
Cash and cash equivalents, beginning of period	554,556	1,443,349
Cash and cash equivalents, end of period	12,298	1,368,118
Supplemental disclosures of cash flow information
Cash paid for interest	613,600	631,471
Supplemental disclosures of non-cash investing and financing activities
Accrued guaranteed payments and deferred expenses related to purchased patents	0	923,928
Conversion of portion of short term note payable, related party, to purchase common stock	0	100,000
Fair value of common stock warrants	$ 4,154,620	$ 41,305